Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain

Vaccination against Community-Acquired Pneumonia in Spanish Adults: Practical Recommendations by the NeumoExperts Prevention Group

(2023) Esther Redondo et al.   Antibiotics-Basel

Compliance to Advisory Committee on Immunization Practices recommendations for pneumococcal vaccination

(2022) Antonia Morga et al.   VACCINE

Direct Medical Costs of Four Vaccine-Preventable Infectious Diseases in Older Adults in Spain

(2022) Ángel Gil de Miguel et al.   Pharmacoeconomics-Open

Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly

(2022) Shu-ling Hoshi et al.   VACCINE

Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease

(2022) Diana Mendes et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23

(2022) Jens Olsen et al.   JOURNAL OF MEDICAL ECONOMICS

The evolution and distribution of pneumococcal serotypes in adults hospitalized with community acquired pneumonia in Spain using serotype specific urinary antigen detection test: the CAPA study, 2011-2018

(2021) Antoni Torres et al.   CLINICAL INFECTIOUS DISEASES

All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain

(2021) Javier Rejas et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Nationwide trends of invasive pneumococcal disease in Spain (2009-2019) in children and adults during the pneumococcal conjugate vaccine era

(2020) Sara de Miguel et al.   CLINICAL INFECTIOUS DISEASES

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design

(2018) John M McLaughlin et al.   CLINICAL INFECTIOUS DISEASES

Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults

(2018) José A. Suaya et al.   VACCINE

Pneumococcal Disease and the Effectiveness of the PPV23 Vaccine in Adults: A Two-Stage Bayesian Meta-Analysis of Observational and RCT Reports

(2018) Hamid Latifi-Navid et al.   Scientific Reports

Estimating a cost-effectiveness threshold for the Spanish NHS

(2017) Laura Vallejo-Torres et al.   HEALTH ECONOMICS

Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study

(2017) Motoi Suzuki et al.   LANCET INFECTIOUS DISEASES

Incidence and risk factor prevalence of community-acquired pneumonia in adults in primary care in Spain (NEUMO-ES-RISK project)

(2016) I. Rivero-Calle et al.   BMC INFECTIOUS DISEASES

Risk of hospitalization due to pneumococcal disease in adults in Spain. The CORIENNE study

(2016) Ruth Gil-Prieto et al.   Human Vaccines & Immunotherapeutics

Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain

(2015) Jose Miguel Rodríguez González-Moro et al.   CLINICAL DRUG INVESTIGATION

Long-term mortality of hospitalized pneumonia in the EPIC-Norfolk cohort

(2015) P. K. MYINT et al.   EPIDEMIOLOGY AND INFECTION

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

(2015) Marie-Josée J. Mangen et al.   EUROPEAN RESPIRATORY JOURNAL

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

(2015) Marc J.M. Bonten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pneumococcal infection in adults: burden of disease

(2013) J.J.C. Drijkoningen et al.   CLINICAL MICROBIOLOGY AND INFECTION

Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions

(2013) Bo-Hyun Cho et al.   VACCINE

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy

(2013) Sara Boccalini et al.   Human Vaccines & Immunotherapeutics

The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England

(2012) Albert Jan van Hoek et al.   JOURNAL OF INFECTION

Análisis de coste-efectividad de la vacunación antineumocócica en España

(2011) Raúl Morano et al.   Gaceta Sanitaria

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain)

(2011) Javier Díez-Domingo et al.   VACCINE